Culture-expanded MSC injections

This is a different product from the "stem cell" injections sold in US clinics. Culture-expanded MSCs are defined doses — 10 to 100-plus million cells — grown over weeks from bone marrow, adipose, or umbilical cord tissue in a GMP facility. The proposed mechanism is paracrine: anti-inflammatory and anti-catabolic signaling and synovial macrophage modulation, not engraftment. Human mechanistic support exists — dose-dependent reductions in MRI synovitis and cartilage catabolic biomarkers after autologous bone-marrow MSCs, and decreased poor-cartilage area on T2 mapping after allogeneic cells.

The positive trials

The randomized evidence is small but unusually consistent:

Lee 2019, a double-blind phase IIb, gave 24 patients a single 100-million autologous adipose MSC injection or saline. WOMAC improved significantly at 6 months in the cell group only, and cartilage defects held stable on MRI while controls progressed.

Lamo-Espinosa's multicenter phase I/II randomized 30 patients to bone-marrow MSCs at 10 or 100 million cells plus HA, versus HA alone. The high-dose group improved ~16.5 WOMAC points at 12 months with no joint-space narrowing while controls narrowed — and at 4 years both cell groups still held their pain and WOMAC gains (median VAS 2–3 versus 7), the field's best durability signal.

Vega 2015 found a single 40-million dose of allogeneic — off-the-shelf donor — bone-marrow MSCs beat HA on algofunctional indices with improved cartilage quality on T2 mapping at one year. Matas 2019 found repeated umbilical-cord MSC dosing beat HA on WOMAC pain at 12 months, with single dosing intermediate. An open-label dose escalation adds a coherent dose-response: 50 million cells performed best, with dose-dependent synovitis and biomarker reductions.

The cautionary large trial

The one large randomized test of a culture-expanded product is the umbilical-cord-tissue MSC arm of Mautner 2023 (480 patients): not superior to a corticosteroid injection at 12 months. Every positive trial above has 10–15 patients per arm — effects of that size routinely shrink at scale. Sponsor entanglement is real (Lee funded by R-Bio; Matas authors employed by Cells for Cells; Freitag's positive trial had no sham injection and an author-affiliated clinic), and the HA comparators and co-injections in several trials muddy attribution.

Regulatory status, plainly

Culture-expanded MSCs are unambiguously a biologic drug in the US: not FDA-approved for any orthopedic indication, and injection outside an IND or clinical trial is unlawful. US clinics advertising "stem cell injections" are selling either non-expanded products (BMAC, SVF — see those entries) or unapproved drugs. Approved products exist abroad — Cartistem, an allogeneic umbilical-cord product, in Korea — so true culture-expanded MSCs are accessible only through registered trials or medical tourism, with the quality-control risk that implies.

Dosing signals

Higher doses look better (100M over 10M; 50M over 1–10M) and repeated dosing beat single dosing in the Matas trial. Autologous products require weeks of manufacturing lead time; allogeneic cells worked as well as autologous in the one small trial that tested them, with theoretical immunization concerns not observed clinically at these scales.

Safety

No serious adverse events across the cited trials; transient injection-site pain and swelling are common. The practical safety issue is unregulated clinics using poorly characterized products under a "stem cell" label.

What would change the tier

An adequately powered, placebo-controlled trial of a defined MSC dose — none has read out — plus answers on autologous versus allogeneic cells, source tissue, and whether the biomarker and imaging signals translate into actual joint preservation.